PIV5-Derived Viral Vectors for Non-Integrating Persistent Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved viral vectors that can be used as adjuvants in medicine for treating diseases like cancer, which are safe and effective in delivering therapeutic compounds without integrating into the host genome and capable of establishing persistent infections for high-level expression of recombinant proteins.
Innovation Solution
Development of PIV5-derived viral vectors, including single cycle vectors and defective interfering particles, which lack certain genes and require helper cell lines to provide missing proteins, enabling persistent infections and high-level expression of therapeutic proteins without producing infectious virus particles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If viral vectors are used to deliver therapeutic compounds, then therapeutic delivery capability is improved, but risk of viral gene integration into host genome increases
Solution Approach 1:
The patent extracts and removes the DNA replication and integration functions from the viral vector system by using a modified PIV5 virus that lacks the ability to integrate into host genomes. The vector delivers therapeutic compounds through RNA-mediated mechanisms that do not require DNA integration, thereby eliminating the harmful effect while preserving the therapeutic delivery capability.
Solution Approach 2:
The patent introduces an intermediary mechanism using RNA-based delivery systems that mediate therapeutic compound delivery without direct genomic integration. The viral vector serves as a carrier that delivers therapeutic RNA or proteins through non-integrating pathways, acting as an intermediary that bypasses the harmful integration step while maintaining delivery effectiveness.
2Duration of action of moving object
If viral vectors establish persistent infections, then duration of therapeutic action is improved, but production of infectious virus particles increases
Solution Approach 1:
The patent extracts the pathogenicity and infectious virus production capabilities from the viral vector by using a attenuated PIV5 strain that can establish persistent infections for prolonged therapeutic action but is engineered to prevent production of infectious virus particles. This separates the beneficial persistent infection feature from the harmful infectious output.
Solution Approach 2:
The patent employs a disposable, non-replicating viral vector system that delivers therapeutic compounds and then decays without producing infectious particles. The viral vector serves its purpose once and is eliminated safely, avoiding the harmful cycle of infectious virus production while maintaining persistent therapeutic effect through controlled gene expression.
3Reliability
If viral vectors are modified to lack certain genes, then safety is improved, but ability to replicate and produce proteins decreases
Solution Approach 1:
The patent makes the viral vector system multi-functional by designing a modified PIV5 vector that can perform multiple functions: delivering therapeutic compounds, establishing persistent infections, and expressing recombinant proteins, while lacking only the harmful genes for integration and infectious particle production. The vector compensates for removed genes through engineered alternative pathways that maintain productivity without compromising safety.
Data Source
AI summary
The present disclosure provides a cohort of novel viral genome derived products for use, for example, in medicine, as a medicaments, as expression vectors and as adjuvants. The disclosed viral genome derived products may be derived from members of the Paramyxoviridae Family which contains a wide variety of vertebrate viruses, including mumps, measles and human parainfluenza viruses.